• Bsa I (RNase-free): Practical DNA Workflow

  2026-09-11

  Bsa I (RNase-free) supports sequence-directed DNA cleavage in cloning, DNA manipulation, and other molecular biology research workflows where RNA contamination must be minimized. It is intended for controlled research use only and should not be used for diagnostic, clinical, or medical applications.

• Validated HPLC Analysis of Trelagliptin Succinate

  2026-09-10

  The reference study developed and validated a stability-indicating HPLC method for quantifying trelagliptin succinate and eight process-related impurities in pharmaceutical dosage forms. Its combination of multi-impurity separation, forced-degradation testing, and UHPLC-Orbitrap mass spectrometric characterization provides a practical quality-control framework for SYR-472 succinate research.

• Lamotrigine Assays: Mechanism to Measurement

  2026-09-10

  Lamotrigine is a chemically defined sodium channel blocker for epilepsy and cardiac research. This guide moves beyond mechanism summaries to show how assay context, analytical controls, and metabolism-aware interpretation improve the reliability of Lamotrigine experiments.

• Trichostatin A: HDAC Workflow for Cancer Research

  2026-09-09

  Build reproducible TSA experiments that connect histone acetylation with proliferation, differentiation, and receptor-defined breast cancer phenotypes. This practical workflow combines dose setting, chromatin validation, cell-cycle analysis, and the CHK1-focused findings of a breast cancer study.

• Tofacitinib: Reframing RA Macrophage Assays

  2026-09-09

  Tofacitinib (CP-690550) links JAK-dependent cytokine signaling to macrophage metabolism and phenotype in rheumatoid arthritis models. This article develops an assay-centered framework for distinguishing proximal STAT5 effects from broader immunometabolic repair.

• Demethyleneberberine and Neurodegenerative Disease

  2026-09-08

  The 2022 review proposes Demethyleneberberine (DMB) as a neuroprotective candidate by connecting antioxidant, mitochondrial, and anti-inflammatory activity with NF-κB, MAPK, and AMPK signaling. Its main value is mechanistic integration rather than clinical proof, giving researchers a framework for evaluating DMB in neuroinflammation, oxidative stress, and disease-specific cellular models.

• Roscovitine: Designing Better CDK Assays

  2026-09-08

  Roscovitine (Seliciclib) is more than a CDK inhibitor: it is a useful calibration tool for connecting biochemical potency, reversible cell-cycle phenotypes, and assay design. This guide shows how to interpret its selectivity and apply it rigorously in cancer biology research.

• Ouabain Workflows for Na+/K+-ATPase Assays

  2026-09-07

  Build mechanism-focused Ouabain experiments that connect sodium-pump inhibition with calcium handling, viability, and cardiac physiology. This guide combines a practical Na+/K+-ATPase inhibition assay workflow with assay-design lessons from cancer drug-response research, while separating product specifications from starting recommendations.

• Stable Yeast Expression of Exendin-4: Study Review

  2026-09-07

  Balius et al. developed recombinant expression models for Exendin-4, also known as Exenatide, in Escherichia coli and Saccharomyces cerevisiae. Chromosomally integrated yeast produced immunoreactive Exendin-4 at the expected size, providing an early synthetic-biology foundation for more accessible production while leaving bioactivity, purification, oral delivery, and therapeutic efficacy unresolved.

• Angiotensin 1/2 (1-6): An Assay-Design Guide

  2026-09-05

  Angiotensin 1/2 (1-6) is a defined Asp-Arg-Val-Tyr-Ile-His hexapeptide for resolving renin-angiotensin system biology. This guide goes beyond product description to explain fragment identity, assay controls, and the evidentiary boundaries of cardiovascular, renal, and spike-receptor research.

• Dextrose in Hypoxic Tumor Immunometabolism

  2026-09-04

  Dextrose (D-glucose) is more than a routine media ingredient: it is a controllable metabolic input for investigating how hypoxia, nutrient competition, and immune dysfunction interact in tumors. This thought-leadership article connects mechanistic findings with experimental design, product selection, and translational decision-making while defining the limits of glucose supplementation models.

• Müller Cell PEDF in Angiopoietin Retinal Survival

  2026-09-04

  The 2026 study by Younis and colleagues identifies Müller cell-derived pigment epithelium-derived factor (PEDF) as a key intermediary connecting angiopoietin signaling with retinal neuron survival. Its co-culture, hypoxia, gene-silencing, and phospho-signaling experiments distinguish the opposing effects of Ang-1 and Ang-2 and provide a framework for mechanistic retinal neurovascular assays.

• Temafloxacin: From PK to Assay Design

  2026-09-03

  Temafloxacin is a fluoroquinolone broad-spectrum antibacterial agent whose pharmacokinetic behavior can guide more interpretable antimicrobial assays. This article connects exposure, tissue distribution, renal clearance, and concentration selection to practical research decisions.

• Canagliflozin Reshapes Renal Mitochondria in Mice

  2026-09-03

  The reference study shows that canagliflozin improves proximal tubular mitochondrial architecture and bioenergetics in hypertensive–diabetic mice, with a stronger functional response in males. Its main contribution is to connect SGLT2 inhibition with renal mitochondrial remodeling and albuminuria improvement beyond glucose lowering alone.

• Docetaxel Workflows for Chemoresistance Research

  2026-09-02

  Build more informative Docetaxel assays by pairing microtubule-driven cytotoxicity with cell-cycle, apoptosis, and multidrug-resistance readouts. A renal cell carcinoma study provides a practical framework for testing how SMYD2 and miR-125b biology may alter response to Taxotere-like treatment.

8141 records 1/543 page Next 12345 下5页 Last page